DMXAA (Vadimezan)

(Synonyms: AS-1404, 5,6-MeXAA, NSC-640488, Vadimezan)
Catalog No.GC16280
DMXAA (Vadimezan) is a selective DT-diaphorase inhibitor with a Ki value of 20μM and an IC50 value of 62.5μM.

Product has been cited by 1 publications
Biochem Pharmacol (2025)：117516.PMID:41187884
Description
DMXAA (Vadimezan) is a selective DT-diaphorase inhibitor with a Ki value of 20μM and an IC50 value of 62.5μM[1]. DMXAA (Vadimezan) is a tumor blood vessel disrupting agent (tumor-VDA) that induces rapid closure of blood flow in tumors to cause tumor regression[2]. DMXAA (Vadimezan) is an agonist of stimulator of interferon genes (STING) and a potent inducer of type I IFN and other cytokines[3]. DMXAA (Vadimezan) is also a multi-kinase inhibitor, specifically targeting VEGFR 2 [4].

In vitro, DMXAA (Vadimezan) (500 μg/mL) treated HECPP cells for 24 hours, inducing 50% cell apoptosis and up-regulating IP-10 mRNA levels [5]. DMXAA (Vadimezan) (0.1μM-10μM) induced G1 arrest in A549 cells in a dose-dependent manner, thereby inducing apoptosis and autophagy, and also increased beclin1 and microtubule-associated protein 1A/1B-light chain in the cells. 3 (LC 3-II) expression is enhanced [6].

read more..